Skip to main content
Download PDF
Download ePub

Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro

Journal of Experimental & Clinical Cancer Research volume 29, Article number: 108 (2010) Cite this article

Abstract

Background

To explore the anti-tumor effects of parthenolide in human pancreatic cancer.

Methods

BxPC-3 cell, a human pancreatic cancer, was treated with parthenolide at different concentrations. The MTT assay was used to analyze cell viability. Flow cytometry and DNA fragmentation analysis were applied to evaluate apoptosis after parthenolide treatment. The wound closure and cell invasion assay were also employed in the study. Western blotting was used to demonstrate Bad, Bcl-2, Bax, caspase-9 and pro-caspase-3 expression.

Results

The MTT assay indicated that the pancreatic cancer growth could be dose-dependently inhibited by parthenoolide. This phenomenon was confirmed by flow cytometry and DNA fragmentation analysis. The wound closure assay and cell invasion assay showed that BxPC-3 cell was significantly suppressed by parthenolide at 7.5 μM and 15 μM. Western Blotting demonstrated the Bcl-2 and pro-caspase-3 were down-regulated while the Bax and caspase-9 were up-regulated. No alteration in Bad expression was found after treatment.

Conclusions

The parthenolide can inhibit the cell growth, migration, and induce the apoptosis in human pancreatic cancer. These findings may provide a novel approach for pancreatic cancer treatment.

Background

Pancreatic adenocarcinoma is among the leading causes of cancer related mortality throughout the world [1]. Currently surgical resection is still the main therapeutic approach. However most cases are unresectable when diagnosed. Even in resectable cases, the long-term outcome remains unsatisfactory. The statistics disclosed that one-year survival rate was less than 10%, 5-year survival rate was less than 1% and median survival duration ranged from three to four months, respectively. The clinic reality mentioned above made chemotherapy essential for a cure. However drug-resistance can compromise the therapeutic effectiveness which is the major concern nowadays [2].

Parthenolide (PTL) is the main extracts of sesquiterpene lactone isolated from Mexican and Indian herbs such as feverfew (Tanacetum parthenium). PTL has been used conventionally to treat migraine and rheumatoid arthritis for centuries [3]. Recently it has been reported that PTL may induce inhibition of proliferation and apoptosis in various human cancer cells in vitro, such as colorectal cancer, hepatoma, cholangiocarcinoma [4–6]. In addition, PTL can sensitize resistant cancer cells to anti-tumor agents [7, 8] and act as a chemo-preventive agent in an animal model of UVB-induced skin cancer [9]. Meanwhile data have showed that PTL-induced apoptosis is associated with inhibition of transcription factor nuclear factor-kappa B (NF-kB) [3, 10], mitochondrial dysfunction and increase of reactive oxygen [11, 12]. However the detailed molecular mechanisms of anticancer effect of PTL are largely unknown.

Our study disclosed that PTL induced apoptosis in BxPC-3 cells mainly by influencing bcl-2 family. PTL and its sesquiterpene lactone analogues might be new chemotherapeutic agents for pancreatic cancer.

Methods

Cell culture and reagents

Human pancreatic cancer cell line BxPC-3 was purchased from Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). It was cultured in dulbecco's modified eagle's medium (DMEM, HyClone, Logan, Utah, USA) containing 10% fetal bovine serum (JRH Biosciences, Lenexa, Kansas, USA), peniciline streptomycin mixture at 37°C in a humidified atmosphere of 5% CO2 and 95% air. Parthenolide (Sigma, St. Louis, MO, USA) supplied as a crystalline solid was dissolved in dimethylsulfoxide (100 mM stock) and stored at -20°C. Antibodies used in this study were obtained from Santa Cruz (CA, USA) and Cell Signaling Technology (CA, USA) respectively.

MTT colorimetric survival assay

BxPC-3 cells were plated at a density of 1.0 × 104 cells per well in 96 well plates. 24 hours after incubation, cells were treated by PTL at indicated concentrations for 48 hours; then the medium was removed and 200 μl of fresh medium plus 20 μl of 3-(4, 5-dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide (MTT, 2.5 mg dissolved in 50 μl of dimethylsulfoxide, Sigma, St. Louis, MO, USA) were added to each well. After incubation for 4 hours at 37°C, the culture medium containing MTT was withdrawn and 200 μl of dimethylsulfoxide(DMSO) was added, followed by shaking for 10 minutes until the crystals were dissolved. Viable cells were detected by measuring absorbance at 570 nm using MRX II absorbance reader (DYNEX Technologies, Chantilly, Virginia, USA). The cell growth was expressed as a percentage of absorbance in cells with PTL treatment to that in cells without PTL treatment (100%). The inhibition rate (IR) was calculated as follows: IR = (1-A value of PTL well/A value of control well) × 100%

Flow Cytometry

1× 105 cells suspended in 2 ml fresh media were plated in each well of a 6-well flat-bottomed microtiter plate and incubated overnight. Then PTL with indicated concentrations were added. After 48 hours cells were harvested and washed twice with pre-cold PBS and then resuspended in 1× binding buffer at a concentration of 1 × 106 cells/ml. 100 μl of such solution (1 × 105 cells) was mixed with 5 μl of annexin V-FITC and 5 μl of Propidium Iodide (PI) (BD Biosciences, San Jose, CA, USA) according to the manufacturer's introduction. The mixed solution was incubated at room temperature (25°C) away from light for 15 minutes. Then 400 μl of 1× dilution buffer was added to each tube. Analysis was performed by Beckman Coulter FC500 Flow Cytometry System with CXP Software (Beckman Coulter, Fullerton, CA, USA) within 1 hour.

DNA fragmentation analysis

BxPC-3 cells (1 × 106 cells) were seeded in 6-well microtiter plate. Then the cells were treated with the indicated concentrations of PTL for 48 hours. For analysis of genomic DNA, attached and nonattached cells in the supernatant were harvested and collected together. DNA was extracted by the DNA extraction kit (QIAGEN, German) according to the manufacturer's instruction. 5 μg of DNA was separated on a 2% agarose gel. DNA in the gel was stained with ethidium bromide, visualized under UV light, and photographed.

Wound closure assay

Cells were plated in 6-well-plates. When the cells grew into full confluency, a wound was created on the monolayer cells by scraping a gap using a micropipette tip and then PTL with indicated concentrations were added immediately after wound creation. The speed of wound closure was compared between PTL treated groups and the control group (PTL untreated cells). Photographs were taken under 100× magnifications using phase-contrast microscopy (OLYMPUS IX70, Olympus, Tokyo, Japan) immediately after wound incision and at later time points as showed.

Cell invasion assay

A Transwell cell culture chamber (Millipore, Bedford, MA, USA) with a 6.5-mm-diameter polycarbonate filters (8-μm pore size) was coated with Matrigel, dried and reconstituted at 37°C with culture medium. Cells were divided into three groups: the control group, 7.5 μM group and 15 μM PTL group. We placed culture medium containing 20% FBS in the lower chamber (24-well-plates). Then the cells at 1 × 105 cells per chamber were added to the upper chamber in DMEM containing 10% FBS. After 48 hours incubation at 37°C the suspended media in the lower chamber were removed. The cells that had invaded to the lower side of the filter were fixed in methanol, stained with GIMSA solution. The number of cells that passed through the pores into the lower chamber was counted under a phase-contrast microscope (Leica DMLB2, Leica Microsystems AG, Wetzlar, Germany) (five fields per chamber).

Western blotting

Proteins were extracted from cultured cells and were subjected to western blot analysis using specific antibodies for bcl-2, caspase-9 and pro-caspase-3 protein. The cells (~2 × 108 cells) were harvested and rinsed twice with PBS after PTL treatment for 48 hours. Cell extracts were prepared with pre-cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF, 2% Cocktail) and cleared by centrifugation at 12000g for 30 minutes at 4°C. Total protein concentration was measured using the BCA assay kit (Sigma) according to the manufacturer's instruction. Cell extracts containing 30 μg of total protein were separated by 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the proteins were electrotransferred onto nitrocellulose membrane (Millipore, Bedford, MA, USA). The membrane was then blocked with TBST (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20) containing 5% w/v nonfat milk, and then incubated with primary antibody (dilution factor, 1:1000) in TBST with gentle agitation overnight at 4°C. The membrane was washed 3 times for 10 minutes incubation with TBST and hybridized with redish-peroxidase (HRP)-conjugated secondary antibody (1:2000 dilution, Dakocytomation corporation, Glostrup, Denmark) corresponding to each primary antibody with gentle agitation for 2 hours at room temperature. Protein bands specific for antibody were visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA).

Statistical analysis

All the detection items in this study were repeated at least 3 times. Statistical analysis was done using SPSS software (Version 13.0, SPSS Inc, Chicago, IL, USA). The data was expressed as mean ± SD. Statistical significance of the differences between the control- and PTL-treated cells was determined by a two-tailed Student's t test with a 95% confidence interval.

Results

PTL inhibited proliferation of the pancreatic cancer cell in a dose-dependent manner

The survival and inhibition rate of BxPC-3 cells following treatment with different PTL concentrations was measured. Cells treated with PTL for 48 hours were compared with PTL-untreated cells. The MTT assay (Fig. 1) demonstrated that treatment with 1 μM and 2 μM for 48 hours insignificantly triggered cell death (P > 0.05 VS control). However, concentrations from 5 μM to 30 μM could markedly inhibit tumor cells (P < 0.01 VS control). The bivariate correlation analysis confirmed the negative relationship between PTL concentrations and cell survival rates and the positive relationship between PTL concentrations and cell inhibition rates. In BxPC-3 cells, EC50 was estimated to be 14.5 μM.

Figure 1
figure 1

PTL inhibited BxPC-3 proliferation. MTT assay demonstrated that PTL can inhibit BxPC-3 cell growth in vitro. Besides, this effect was in a dose-dependent manner. The cell viability and inhibition rates were calculated by comparing with the control group (100%) after 48 hours treatment. Data were presented as mean ± SD (n = 3). Points, mean; bars, + SD. *, P > 0.05; **, P < 0.01 compared with the control group.

Full size image

PTL induced significant apoptosis in human pancreatic cancer cell

To investigate the effect of inducting apoptosis by PTL in BxPC-3 cells, the flow cytometry and DNA fragmentation analysis were preformed. Annexin-V/PI-FACS analysis (Fig. 2A) was applied to quantify the apoptotic phenotype. Annexin-V-positive cells (right quadrant in the density dot plot) were summarized, including early apoptotic and late apoptotic cell death. PTL-treated cells revealed morphologic events of apoptosis more significantly than cells treated with DMSO alone. The inductive effect of apoptosis presented as a concentration-dependent manner. The apoptosis induced was further confirmed using DNA fragmentation analysis (Fig. 2B). Disintegrated nuclei and nonrandom DNA fragmentation were found on gels. More apoptotic internucleosomal DNA fragmentation was observed after higher concentrations of PTL treatment. These results revealed that PTL effectively induced a dose-dependent apoptosis in human pancreatic cancer cell.

Figure 2
figure 2

PTL induced BxPC-3 apoptosis. BxPC-3 cells were treated with the indicated concentrations of PTL for 48 hours. (A) The quantification of apoptosis was estimated by Annexin-V/PI-FACS analysis. As apoptotic events Annexin-V-positive cells (right quadrant in the density dot plot) were summarized. (B) DNA Fragmentation Analysis indicated that the cells treated with higher concentrations of PTL showed higher proportions of apoptotic internucleosomal DNA fragmentation. These results revealed that PTL-induced apoptosis in BxPC-3 cells was in a dose-dependent manner. The data was described as mean ± SD (n = 3) and the representative figures are shown.

Full size image

PTL suppressed BxPC-3 cell migration

Increased migration rate is one of the characteristics in metastatic cancer cells [13]. Pancreatic cancer is a major health problem due to its high risk of metastasis. Accordingly the wound closure assay (Fig. 3) was used to investigate if PTL influenced migration ability of BxPC-3 cells. Wound gap of similar size was created in monolayer BxPC-3 cells at 0 hour. The gap was filled with migrating cells gradually and nearly closed in the control group after 24 hours. Oppositely, the wounds were still widely open at 24 hours after exposure to PTL at indicated concentrations. The results indicated that PTL treatment could inhibit migration of pancreatic cancer cell.

Figure 3
figure 3

PTL suppressed BxPC-3 migration. The wound gap of cells was scratched by a micropipette tip. Cells were incubated in the presence of PTL. 24 hours later the wound gap of BxPC-3 in the control group was nearly closed. On the contrary, after exposure to PTL at 7.5 μM, the speed of wound closure was much slower and the wound was still widely open at twenty-four hours.

Full size image

PTL inhibited BxPC-3 cell invasion

The effect of PTL on BxPC-3 cell invasion was detected by a reconsitituted Matrigel membrane. The number of cells that passed through the filter and into the lower chamber was counted and compared. As a result, PTL at different concentrations obviously inhibited invasive ability of pancreatic cancer cell. The cell numbers of 7.5 μM and 15 μM PTL groups were (94 ± 7)/HPF and (58 ± 8)/HPF respectively, which were less than (146 ± 10)/HPF of control group (P < 0.05) (Fig. 4).

Figure 4
figure 4

PTL inhibited BxPC-3 cells invasion. Cells were fixed, stained and counted at 48 hours. The invasion cell numbers in PTL-treated groups were significantly less than the control group (P < 0.05), which indicated that PTL suppressed cell invasion dose-dependently.

Full size image

PTL downregulated Bcl-2 and upregulated Bax expression. No change was found on Bad

The underlying mechanism of PTL was also explored in the study. The activation of several apoptosis-related proteins may contribute to PTL-induced apoptosis. In Bcl-2 family members, the expression of Bcl-2, Bax and Bad after PTL treatment for 48 hours were detected by Western blotting (Fig. 5A). PTL obviously decreased the protein expression of antiapoptotic Bcl-2 and increased the protein expression of proapoptotic Bax in the BxPC-3 cells after being treated with indicated concentrations. No change was found on Bad. Therefore, the susceptibility to PTL-induced apoptosis might be attributable to the imbalance of Bcl-2/Bax (Fig. 5B).

Figure 5
figure 5

Apoptosis-related protein expression after PTL treatment for 48 hours. (A) PTL decreased Bcl-2 expression and induced Bax expression. No obvious change was observed on Bad; (B) Bcl-2/Bax ratio was decreased significantly with the increasing concentration of PTL; (C) Activation of caspase-9 and caspase-3 after PTL treatment.

Full size image

Effect of PTL at various concentrations on caspase-9 and caspase-3 expression

Data have showed many anticancer agents are capable of initiating the caspase activation and inducing apoptosis [14]. Hence the caspase cascade in PTL-induced effect was also analyzed. After PTL treatment at indicated concentrations for 48 hours, Caspase-9 and Pro-caspase-3 expressions of BxPC-3 cell were explored (Fig. 5C). The dose-dependent proteolytic cleavage of caspase-9 was detected. Following caspase-9 activation, Pro-caspase-3 expression was downregulated significantly. Therefore, PTL-induced apoptosis was confirmed to be caspase-dependent.

Discussion

Pancreatic cancer is a major unsolved health problem because of its biological aggressiveness. In the last decade, traditional clinical cancer therapy regimens as surgical tumor resection, cytotoxic chemotherapy, and radiation therapy have been supplemented with individualized targeted therapies directed against molecular determinants of the tumor. In spite of improved multimodal therapeutic regimens, 5 year survival does not exceed 5 percent. Inherent or acquired resistance towards cytotoxic agents, ionizing radiation, or both, is one of the hallmarks of biological aggressiveness of pancreas cancer as a solid tumor. To develop a new chemotherapeutic agent is still a clinical major concern as well as the better understanding of etiopathogenesis and molecular biology of pancreatic cancer.

NF-kB is ubiquitous and can be detected in the cytoplasm of many cell types. Several researches have indicated that constitutive NF-kB activation may conduce to pancreatic tumorigenesis [15, 16]. Hence, the chemotherapeutic potential of NF-kB inhibitors should be evaluated. PTL is one of the traditional medicines extracted from medical herb Feverfew in European and American. Studies have shown that PTL targets NF-kB via inhibition of the upstream regulator IkB kinase (IKK) [17] which phosphorylates IkB and targets it for proteasomal degradation. PTL and its analogues have recently been shown to inhibit proliferation, suppress invasiveness and induce apoptosis of several human cancer cells [4–6, 18]. Further studies indicate that in vitro and vivo PTL and its analogues-induced growth inhibition and apoptosis is associated with NF-kB pathway, and the effect is more significant combined with COX inhibitor [12, 19]. But the detailed and precise mechanism underlying PTL induced apoptosis remains unclear which attracted our interest.

In our study it was found that PTL significantly inhibited growth of BxPC-3 cells. MTT assay demonstrated a dramatic loss of viability of cancer cell which was treated with PTL in a dose-dependent fashion. Next PTL-induced apoptosis was observed. Flow cytometry indicated that PTL conspicuously induced apoptosis which was confirmed by DNA fragmentation analysis. Meanwhile the migration and invasion assay indicated that PTL effectively suppressed cancer cell movement. Data mentioned above demonstrated PTL might be a novel chemotherapeutic agent.

In order to explore the molecular mechanism of PTL-induced apoptosis in BxPC-3 cell, several genes were detected. Wang et al [20] demonstrated that combination therapy with PTL and arsenic trioxide inhibited the growth of pancreatic cancer cells via the mitochondrial pathway. Researches have reported that Bcl-2 family members are associated with mitochondria-related apoptosis [21, 22]. As main members of Bcl-2 family, the antiapoptotic gene Bcl-2 and proapoptotic gene Bax were analyzed in most human cancers which played important roles in tumorigenesis and development [23]. Bcl-2 and Bax localize at the outer membrane of mitochondrial. The balance between them prevents translocation of cytochrome-c from the mitochondria and determines the apoptosis resistance. Inhibition of Bcl-2 or induction of Bax breaks the balance between two genes (as showed in Fig.5B), resulting in mitochondrial dysfunction and cytochrome-c release [21, 22]. Researches have demonstrated that several Bcl-2 family members are regulated by NF-kB [24, 25]. Promoter analysis showed Bcl-2 had multiple putative NF-kB binding sites [26, 27]. Meanwhile, inhibition of NF-kB depressed Bcl-2 expression [28].

Caspases, a family of cysteine proteases, play a critical role in the execution of apoptosis [29] which are modulated by several upstream genes, especially cytochrome-c [30]. Once cytochrome-c is released into cytoplasm, it binds to the adaptor molecule, Apaf-1, and forms the apoptosome that activates caspase-9. Activated caspase-9 cleaves and activates procaspase-3 [31]. In our study data showed that Bcl-2 and procaspase-3 proteins were down-regulated after PTL treatment with the Bax and caspase-9 protein up-regulated. Mitochondrial involvement contributing to the mechanism of PTL-induced apoptosis included NF-kB-mediated Bcl-2 down-regulation and Bax up-regulation, release of mitochondrial cytochrome-c to the cytoplasm and activation of caspase-9 and caspase-3.

In summary, PTL might be a new agent which can effectively inhibit proliferation, invasion and induce apoptosis in pancreatic cancer. Although the molecular mechanisms for the PTL-induced effect still need to be clarified, our data showed that the Bcl-2 family molecules and caspase cascade reaction may be involved. Further studies in vivo should be designed to verify the PTL-induced effect.

Conclusions

NF-kB inhibitor PTL may be an agent which can effective against pancreatic cancer, because they can effectively inhibit cell proliferation, induce cell apoptosis and suppress metastatic activity. Although the molecular mechanism(s) for the PTL-induced cancer cell apoptosis are poorly understood, the Bcl-2 family molecules and caspase cascade reaction might be involved. Therefore, NF-kB specific inhibitors include PTL may be applicable to a chemotherapeutic strategy for pancreatic cancer. But this possibility should be followed-up with further comprehensive studies.

References

  1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA-Cancer J Clin. 2004, 54: 8-29. 10.3322/canjclin.54.1.8.

    Article  Google Scholar 

  2. Safioleas MC, Moulakakis KG: Pancreatic cancer today. Hepatogastroenterology. 2004, 51: 862-868.

    Google Scholar 

  3. Pozarowski P, Halicka DH, Parzykiewicz Z: NF-kappaB inhibitor sesquiterpene parthenolide induces concurrently a typical apoptosis and cell necrosis: difficulties in identification of dead cells in such cultures. Cytometry A. 2003, 54: 118-124. 10.1002/cyto.a.10057.

    Article  Google Scholar 

  4. Zhang S, Ong CN, Shen HM: Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett. 2004, 208: 143-153. 10.1016/j.canlet.2003.11.028.

    Article  CAS  Google Scholar 

  5. Park JH, Liu L, Kim IH, Kim JH, You KR, Kim DG: Identification of the genes involved in enhanced fenretinide-induced apoptosis by parthenolide in human hepatoma cells. Cancer Res. 2005, 65: 2804-2814. 10.1158/0008-5472.CAN-04-2221.

    Article  CAS  Google Scholar 

  6. Kim JH, Liu L, Lee SO, Kim YT, You KR, Kim DG: Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res. 2005, 65: 6312-6320. 10.1158/0008-5472.CAN-04-4193.

    Article  CAS  Google Scholar 

  7. Zhang S, Lin ZN, Yang CF, Shi X, Ong CN, Shen HM: Suppressed NF-{kappa}B and sustained JNK activation contribute to the sensitization effect of parthenolide to TNF-{alpha}-induced apoptosis in human cancer cells. Carcinogenesis. 2004, 25: 2191-2199. 10.1093/carcin/bgh234.

    Article  CAS  Google Scholar 

  8. Nakshatri H, Rice SE, Bhat-Nakshatri P: Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene. 2004, 23: 7330-7344. 10.1038/sj.onc.1207995.

    Article  CAS  Google Scholar 

  9. Won YK, Ong CN, Shi X, Shen HM: Chemopreventive activity of parthenolide against UVB-induced skin cancer and its mechanisms. Carcinogenesis. 2004, 25: 1449-1458. 10.1093/carcin/bgh151.

    Article  CAS  Google Scholar 

  10. Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM: Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther. 2005, 4: 587-594. 10.1158/1535-7163.MCT-04-0215.

    Article  CAS  Google Scholar 

  11. Ross JJ, Arnason JT, Birnboim HC: Low concentrations of the feverfew component parthenolide inhibit in vitro growth of tumor lines in a cytostatic fashion. Planta Med. 1999, 65: 126-129. 10.1055/s-1999-13972.

    Article  CAS  Google Scholar 

  12. Wen J, You KR, Lee SY, Song CH, Kim DG: Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem. 2002, 277: 38954-38964. 10.1074/jbc.M203842200.

    Article  CAS  Google Scholar 

  13. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.

    Article  CAS  Google Scholar 

  14. Fulda S, Debatin KM: Death receptor signaling in cancer therapy. Curr Med Chem Anti-Canc Agents. 2003, 3: 253-262. 10.2174/1568011033482404.

    Article  CAS  Google Scholar 

  15. Wang W, Abbruzzese JL, Evans DB, Chiao PJ: Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 1999, 18: 4554-4563. 10.1038/sj.onc.1202833.

    Article  CAS  Google Scholar 

  16. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, Schmid RM: Stat3 and NF-λB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology. 2002, 123: 2052-2063. 10.1053/gast.2002.37075.

    Article  CAS  Google Scholar 

  17. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM: The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkB kinase. Chem Biol. 2001, 8: 759-766. 10.1016/S1074-5521(01)00049-7.

    Article  CAS  Google Scholar 

  18. Yip-Schneider MT, Wu H, Njoku V, Ralstin M, Holcomb B, Crooks PA, Neelakantan S, Sweeney CJ, Schmidt CM: Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas. 2008, 37: e45-e53. 10.1097/MPA.0b013e318172b4dd.

    Article  CAS  Google Scholar 

  19. Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM: Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther. 2007, 6: 1736-1744. 10.1158/1535-7163.MCT-06-0794.

    Article  CAS  Google Scholar 

  20. Wang W, Adachi M, Zhang R, Zhou J, Zhu D: A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Pancreas. 2009, 38: e114-e123. 10.1097/MPA.0b013e3181a0b6f2.

    Article  CAS  Google Scholar 

  21. Adams JM, Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 1998, 281: 1322-1326. 10.1126/science.281.5381.1322.

    Article  CAS  Google Scholar 

  22. Gross A, McDonnell JM, Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Gene Dev. 1999, 13: 1899-1911. 10.1101/gad.13.15.1899.

    Article  CAS  Google Scholar 

  23. Dong M, Zhou JP, Zhang H, Guo KJ, Tian YL, Dong YT: Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J G. 2005, 11: 2744-2747.

    CAS  Google Scholar 

  24. Wang CY, Guttridge DC, Mayo MW, Baldwin AS: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999, 19: 5923-5929.

    Article  CAS  Google Scholar 

  25. Kurland JF, Kodym R, Story MD, Spurgers KB, McDonnell TJ, Meyn RE: NF-kB1 (p50) homodimers contribute to transcription of the bcl-2 oncogene. J Biol Chem. 2001, 276: 45380-45386. 10.1074/jbc.M108294200.

    Article  CAS  Google Scholar 

  26. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, Bours V: NF-kappa B2/p100 induces Bcl-2 expression. Leukemia. 2003, 17: 1349-1356. 10.1038/sj.leu.2402982.

    Article  CAS  Google Scholar 

  27. Catz SD, Johnson JL: Transcriptional regulation of Bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene. 2001, 20: 7342-7345. 10.1038/sj.onc.1204926.

    Article  CAS  Google Scholar 

  28. Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ: Targeting BCL-2 overexpression in various human malignancies through Nf-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmaco1. 2005, 56: 46-54. 10.1007/s00280-004-0944-5.

    Article  CAS  Google Scholar 

  29. Salvesen GS, Dixit VM: Caspases: mtracellular signaling by proteolysis. Cell. 1997, 91: 443-446. 10.1016/S0092-8674(00)80430-4.

    Article  CAS  Google Scholar 

  30. Du C, Fang M, Li Y, Wang X, Smac A: Mitochondrial protein that promotes cytochrome-c dependent caspase activation by eliminating IAP inhibition. Cell. 2000, 102: 43-53. 10.1016/S0092-8674(00)00008-8.

    Article  Google Scholar 

  31. Zou H, Li Y, Liu X, Wang X: An APAF-1.cytochrome-c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 1999, 274: 11549-11556. 10.1074/jbc.274.17.11549.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study is supported by grants from the Science and Technology Department of Zhejiang Province (No. 021107241 and No. 2005C23037) and the Administration of Traditional Chinese Medicine of Zhejiang Province (No. 2002C042).

Author information

Author notes

    Authors and Affiliations

    1. Department of General Surgery, Sir Run Run Shaw Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, PR China

      Jun-Wei Liu, Ying Xin, Qing-Song Wu, Jun Ma, Po Yang & Dong-Sheng Huang

    2. Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health and Department of Hepato-Biliary-Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, PR China

      Min-Xia Cai & Hai-Yang Xie

    Authors
    1. Jun-Wei Liu
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Min-Xia Cai
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Ying Xin
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Qing-Song Wu
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Jun Ma
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Po Yang
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Hai-Yang Xie
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Dong-Sheng Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Dong-Sheng Huang.

    Additional information

    Competing interests

    The authors declare that they have no competing interests.

    Authors' contributions

    JWL, MXC and YX carried out the molecular experiment and drafted the manuscript. QSW and JM carried out the collection of tissue sample. PY and HYX participated in the design of the study and performed the statistical analysis. DSH conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

    Jun-Wei Liu, Min-Xia Cai contributed equally to this work.

    Authors’ original submitted files for images

    Rights and permissions

    Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Reprints and permissions

    About this article

    Cite this article

    Liu, JW., Cai, MX., Xin, Y. et al. Parthenolide induces proliferation inhibition and apoptosis of pancreatic cancer cells in vitro. J Exp Clin Cancer Res 29, 108 (2010). https://doi.org/10.1186/1756-9966-29-108

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1186/1756-9966-29-108

    Keywords

    Journal of Experimental & Clinical Cancer Research

    ISSN: 1756-9966

    Contact us